SKIBSTED RUSSELL

CFO Russell Skibsted buys 2,190 shares amid coordinated insider buying cluster; stock near 52-week lows.

Processa Pharmaceuticals' CFO Russell Skibsted is buying shares at depressed valuations—the stock is trading well below its annual highs after significant declines over recent months. What makes this noteworthy is that Skibsted's purchase is part of a broader cluster of three insiders buying within a two-week window, suggesting coordinated confidence rather than isolated portfolio activity. This is noteworthy given the company's challenged fundamentals: Processa is unprofitable with sharply declining revenues, and the CFO's purchase of over half his existing holdings represents a meaningful personal commitment at a time when the company needs to demonstrate operational stability. The question for investors is whether this cluster reflects insiders genuinely believing the stock is oversold at current levels, or whether they're simply averaging down in a struggling biotech.

CFO Russell Skibsted buys 1,984 shares of PCSA at $2.97; stock down -74.1% from 52-week high of $11.97

Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals, purchased 1,984 shares on 2026-04-15 at $2.97, increasing his holdings by 85.4% to 4,308 shares post-transaction. The purchase comes while the stock trades at $3.10, down -74.1% from its 52-week high of $11.97, and the company reported zero revenue and a net loss of -$3,436,573.00 in its latest quarter. A cluster pattern is present, with 5 other insiders also buying within the past 14 days. However, the CFO's cross-ticker track record shows only 1 prior buy with no measurable outcomes yet, providing limited context for assessing his historical execution at this ticker.

CFO Russell Skibsted buys 2,324 shares at $2.54 amid cluster of 8 other insider purchases in 14 days

Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals, purchased 2,324 shares at $2.54 on 2026-03-31, establishing an initial position. This buy occurs within a coordinated window: 8 other insiders also purchased within the past 14 days, forming a distinct cluster buy pattern. The company's financial position shows significant weakness—revenue stands at $0.00 (latest quarter) and net income is $-3,436,573.00 with a market cap of $6,916,101.40—yet multiple insiders are acquiring simultaneously rather than abstaining. The current price of $2.60 places the stock at -78.3% from its 52-week high of $11.97, a substantial decline from recent history that coincides with the timing of these insider purchases.